Antiviral Antibody-Omics

Antibodies are key components of the adaptive immune system and are critical for defending against infectious diseases. In our research group, we strive to gain a better understanding of the mechanisms of antibody-mediated protection, with the ultimate objective of creating novel and more effective vaccine and treatment strategies for infectious diseases.
The junior research group is based at TWINCORE in Hannover.


Dr rer nat Yannic Bartsch

Yannic Bartsch is the head of the Junior Research Group "Anti-viral Antibody-omics" at TWINCORE, a joint venture of the Helmholtz Centre for Infection Research (HZI) and the Hannover Medical School (MHH). His primary research focus is the analysis and understanding of the role of antibody-mediated effects in both health and disease, with a goal of utilising antibodies to mitigate disease. Yannic received his PhD from the University of Lübeck in Germany, where he investigated the protective effects of IgG Fc sialylation in murine models of autoimmune disease, as well as the mechanisms of adjuvant-dependent modification of IgG glycosylation upon vaccination in mice. As a postdoctoral researcher at the Ragon Institute of Mass General, MIT, and Harvard in Cambridge (USA), Yannic Bartsch studied the role of antibody Fc effector functions in viral infections, including HIV and SARS-CoV-2, under the mentorship of Prof Galit Alter and Prof Boris Julg. He made significant contributions to the field by addressing the role of Fc-mediated antibody effector functions in respiratory syncytial virus (RSV) infection and vaccination, and showing the relevance of Fc effector functions for protection from RSV infections. His research has resulted in numerous peer-reviewed first-author publications in high-impact journals.

PrintSend per emailShare